Person:
Ganguli, Suvranu

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Ganguli

First Name

Suvranu

Name

Ganguli, Suvranu
Author's Publications: search.filters.isAuthorOfPublication.83ba7b79-a4ce-4f01-a25b-00106ee048e1

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Publication
    Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
    (SAGE Publications, 2017) Kis, Bela; El-Haddad, Ghassan; Sheth, Rahul A.; Parikh, Nainesh S.; Ganguli, Suvranu; Shyn, Paul B.; Choi, Junsung; Brown, Karen T.
    Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC) are primary liver cancers where all or most of the tumor burden is usually confined to the liver. Therefore, locoregional liver-directed therapies can provide an opportunity to control intrahepatic disease with minimal systemic side effects. The English medical literature and clinical trials were reviewed to provide a synopsis on the available liver-directed percutaneous therapies for HCC and IHC. Locoregional liver-directed therapies provide survival benefit for patients with HCC and IHC compared to best medical treatment and have lower comorbid risks compared to surgical resection. These treatment options should be considered, especially in patients with unresectable disease.
  • Thumbnail Image
    Publication
    Yttrium-90 Radioembolization of Hepatic Metastases from Colorectal Cancer
    (Frontiers Media S.A., 2014) Raval, Mihir; Bande, Dinesh; Pillai, Anil K.; Blaszkowsky, Lawrence; Ganguli, Suvranu; Beg, Muhammad S.; Kalva, Sanjeeva P.
    Liver metastases from colorectal cancer (CRC) result in substantial morbidity and mortality. The primary treatment is systemic chemotherapy, and in selected patients, surgical resection; however, for patients who are not surgical candidates and/or fail systemic chemotherapy, liver-directed therapies are increasingly being utilized. Yttrium-90 (Y-90) microsphere therapy, also known as selective internal radiation therapy (SIRT) or radioembolization, has proven to be effective in terms of extending time to progression of disease and also providing survival benefit. This review focuses on the use of Y-90 microsphere therapy in the treatment of liver metastases from CRC, including a comprehensive review of published clinical trials and prospective studies conducted thus far. We review the methodology, outcomes, and side effects of Y-90 microsphere therapy for metastatic CRC.
  • Thumbnail Image
    Publication
    Beyond Hepatocellular Carcinoma and Colorectal Metastasis: The Expanding Applications of Radioembolization
    (Frontiers Media S.A., 2014) Zurkiya, Omar; Ganguli, Suvranu
    As a relatively safe outpatient procedure, radioembolization can potentially be used to treat any type of tumor within the liver, primary or metastatic. The safety and effectiveness of radioembolization in the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC) has led many groups to explore its application in other malignancies. Moreover, other organs, such as the lungs and kidneys, have been explored as targets for therapy. Although the most data for radioembolization is related to HCC and mCRC, there is increasing experience and data regarding metastatic disease to the liver for other primary tumors. We review the current state of liver-directed therapy with radioembolization outside of HCC and mCRC, including metastatic neuroendocrine, breast, and melanoma, as well as limited experiences with other primary malignancies. Applications of radioembolization related to these other cancers and new trends and future directions will be discussed. With increasing use and availability of radioembolization, it promises to serve an expanding role in the repertoire of tools available for treating and managing oncologic disease.
  • Thumbnail Image
    Publication
    Blood pool contrast agents for venous magnetic resonance imaging
    (AME Publishing Company, 2016) Oliveira, Irai S.; Hedgire, Sandeep; Li, Weier; Ganguli, Suvranu; Prabhakar, Anand
    Imaging of the venous system plays a vital role in the diagnosis and management of a wide range of clinically significant disorders. There have been great advances in venous imaging techniques, culminating in the use of magnetic resonance venography (MRV). Although MRV has distinct advantages in anatomic and quantitative cross sectional imaging without ionizing radiation, there are well-known challenges in acquisition timing and contrast administration in patients with renal impairment. The latest advancement involves the addition of new contrast media agents, which have emerged as valuable alternatives in these difficult scenarios. In this review, we will focus on a group of specific contrast agents called blood pool agents and discuss their salient features and clinical applications.